Abstract
The search for an ideal anticoagulant has spanned decades and has resulted in several approaches and the identification of novel target molecules for preventing and treating thrombosis. The first group of new anticoagulant agents acting through direct inhibition of coagulation factors were inhibitors of thrombin, but factor Xa inhibitors and, most recently, factor VIIa inhibitors have become attractive candidates. The structures of thrombin, factor Xa and factor VIIa show similarities in their active sites and, for this reason, attempts have been made to develop synthetic agents containing in a single molecule inhibitory activity against two of the enzymes of the blood coagulation cascade. Such dual inhibitors are now in preclinical studies and are, potentially, new anticoagulant drugs with improved properties. The emphasis of this review will be placed on dual inhibitors of thrombin / factor Xa and factor Xa / factor VIIa. Comparison of the active sites of these enzymes is included for better understanding of the structural demands to be met in designing effective dual inhibitors.
Keywords: anticoagulants, dual inhibitors, thrombin, factor vIIa, factor xa
Current Medicinal Chemistry
Title: Dual Inhibitors of the Blood Coagulation Enzymes
Volume: 11 Issue: 19
Author(s): A. Kranjc and D. Kikelj
Affiliation:
Keywords: anticoagulants, dual inhibitors, thrombin, factor vIIa, factor xa
Abstract: The search for an ideal anticoagulant has spanned decades and has resulted in several approaches and the identification of novel target molecules for preventing and treating thrombosis. The first group of new anticoagulant agents acting through direct inhibition of coagulation factors were inhibitors of thrombin, but factor Xa inhibitors and, most recently, factor VIIa inhibitors have become attractive candidates. The structures of thrombin, factor Xa and factor VIIa show similarities in their active sites and, for this reason, attempts have been made to develop synthetic agents containing in a single molecule inhibitory activity against two of the enzymes of the blood coagulation cascade. Such dual inhibitors are now in preclinical studies and are, potentially, new anticoagulant drugs with improved properties. The emphasis of this review will be placed on dual inhibitors of thrombin / factor Xa and factor Xa / factor VIIa. Comparison of the active sites of these enzymes is included for better understanding of the structural demands to be met in designing effective dual inhibitors.
Export Options
About this article
Cite this article as:
Kranjc A. and Kikelj D., Dual Inhibitors of the Blood Coagulation Enzymes, Current Medicinal Chemistry 2004; 11 (19) . https://dx.doi.org/10.2174/0929867043364432
DOI https://dx.doi.org/10.2174/0929867043364432 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Identification of High Affinity Bioactive Salbutamol Conformer Directed Against Mutated (Thr164Ile) Beta 2 Adrenergic Receptor
Current Topics in Medicinal Chemistry NMDA Pathology and Treatment of Schizophrenia
Current Pharmaceutical Design <i>Arthrophytum scoparium</i> Extract Improves Memory Impairment and Affects Acetylcholinesterase Activity In Mice Brain
Current Pharmaceutical Biotechnology Structure and Function of the Myelin Proteins: Current Status and Perspectives in Relation to Multiple Sclerosis
Current Medicinal Chemistry Capillary Electrophoresis with Mass Spectrometry: Applications to Metabolomic Analysis
Current Metabolomics Fibromyalgia
Current Rheumatology Reviews Direct Production of Reactive Oxygen Species from Aggregating Proteins and Peptides Implicated in the Pathogenesis of Neurodegenerative Diseases
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Cancer Chemoprevention by Targeting the Epigenome
Current Drug Targets Possible Usefulness of Growth Hormone/Insulin-like Growth Factor-I Axis in Alzheimer’s Disease Treatment
Endocrine, Metabolic & Immune Disorders - Drug Targets Essential Structural Features of Novel Antischizophrenic Drugs: A Review
Medicinal Chemistry Analysis of Electrical Brain Waves in Neurotoxicology: Gamma- Hydroxybutyrate
Current Neuropharmacology The Activated Endocannabinoid System in Atherosclerosis: Driving Force or Protective Mechanism?
Current Drug Targets Gadd45 Proteins as Critical Signal Transducers Linking NF-κB to MAPK Cascades
Current Cancer Drug Targets Synthesis, Characterization and Antimicrobial Activity of Pyridine-3- Carbonitrile Derivatives
Current Bioactive Compounds Increased Susceptibility to Oxidative Death of Lymphocytes from Alzheimer Patients Correlates with Dementia Severity
Current Alzheimer Research Pramipexole Tachyphylaxis and its Management in Bipolar Depression
Letters in Drug Design & Discovery Obesity: Current Treatment and Future Horizons
Mini-Reviews in Medicinal Chemistry Triazole and Oxadiazole Containing Natural Products: A Review
The Natural Products Journal Gene Expression Under the Influence: Transcriptional Profiling of Ethanol in the Brain
Current Psychopharmacology Negative Air Ions in Neuropsychiatric Disorders
Current Medicinal Chemistry